Astra Zeneca withdraws durvalumab (Imfinzi) indication in the US for advanced bladder cancer

Withdrawal was based on the results of the Phase III DANUBE trial in which durvalumab monotherapy failed to meet primary endpoints of improving overall survival vs standard of care, in tumour cells and/or tumour-infiltrating immune cells expressing high levels of PD-L1.

Source:

PharmaTimes